SK Bioscience Co. Ltd. and Vaxxas Pty. Ltd. have entered into a joint development agreement that could revolutionize vaccines by developing a vaccine-delivery device combination product using Vaxxas’ high-density microarray patch (HD-MAP) coupled with SK Bioscience’s typhoid vaccine, Skytyphoid.
By Kwanwoo Jun SK Bioscience Co Ltd. s shares rallied Thursday after the global phase 3 clinical trials confirmed the efficacy and safety of its Covid-19 vaccine booster. Shares of the. | April 13, 2023
(Reuters) - SK Bioscience Co Ltd chief executive Jaeyong Ahn said in a Financial Times interview that it is unlikely that the vaccine maker can supply.
The COVID-19 antiviral drug is currently covered by the country's broad healthcare insurance scheme under temporary measures the regulator introduced in March last year as outbreaks rose. 'Life is moving forward': China declares new COVID phase China braced for a "new phase" in its battle against COVID-19 on Monday and financial markets strengthened after Beijing dropped pandemic border controls in the latest easing of curbs that has let the virus loose on its 1.4 billion population.
(Reuters) - SK Bioscience Co Ltd chief executive Jaeyong Ahn said in a Financial Times interview that it is unlikely that the vaccine maker can supply.